Skip to main content
Clinical Trials/CTRI/2020/01/022981
CTRI/2020/01/022981Not yet recruiting未知

Study of cutaneous vasculitis, vascular coagulopathies and their clinico-pathological correlation

GCS Medical College Hospital and Research Centre0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • Patients of either sex and of all age group.
  • Patient presenting clinical sign and symptoms suggestive of cutaneous vasculitis or
  • vasculopathy like,
  • 1) Palpable purpura
  • 2) Petechiae
  • 3) Macular purpura
  • 4)Urticarial papules
  • 5) Vesicles
  • 6)Pustules
  • 7)Targeted papules and plaques
  • 8) Livedo racemosa
  • 9)Retiform purpura
  • 11)Subcutaneous nodules
  • 12)Digital necrosis
  • 13)Erythema
  • 14)Cyanotic skin
  • 15)Livedo reticularis
  • 16)Atrophie blanche
  • 17)Ecchymotic streak
  • 18)Any other on PI discretion.

Exclusion Criteria

  • 1)All patient not willing to give consent
  • 2)Any systemic vascultis case without cutaneous manifestations.
  • Patients having pre-existing or detected during study work up any other disease which
  • mimic cutaneous vasculitis and diseases involving vessel walls other than livido
  • vasculopathy and malignant atrophic papulosis will be excluded from final analysis.
  • Following is list of such disorders.( this is not definite list any other compounding
  • factor on PI discretion will be excluded from final analysis.)
  • 3)Patient with hemostatically relevant thrombocytopenia (<50,000/cu mm) in following
  • Idiopathic thrombocytopenic purpura
  • Thrombotic thrombocytopenic purpura
  • Disseminated intravascular coagulation
  • Thrombocytopenia due to 1) drug related peripheral destruction (eg quinine, quinidine)
  • 2) Drug induced decreased production, idiosyncratic or dose related (eg chemotherapy) 3)
  • Bone marrow infiltration, fibrosis or failure
  • 4) Patient with congenital or hereditary platelet function defects
  • 5)Patient with acquired platelet function defects due to 1) Aspirin, NSAIDs 2) Renal
  • insufficiency 3) Monoclonal gammopathy
  • 6)Patient with thrombocytosis secondary to myeloproliferative disorders (often >1000000/cu
  • 7)Patient with occlusion primarily due to microvascular platelet plugs like heparin necrosis
  • 8)Patient with cold related gelling or agglutination like in 1)cryoglobulinemia , monoclonal
  • 2) cryofibrinogenemia 3) cold agglutinins
  • 9)Patient with vessel â?? invasive fungi
  • 10)Patient with ecthyma gangrenosum
  • Patient with disseminated strongyloidiasis
  • 12)Patient with Protein C and S related 1) Homozygus protein C or protein S deficiency 2)
  • Acquired protein C deficiency 3) Coumadin /Warfarin necrosis (protein C dysfunction) 4)
  • post infectious purpura fulminans (protein S dysfunction)
  • 13) Patient with antiphospholipid antibody,lupus anticoagulant
  • Patient with Sneddon syndrome (vascular coagulopathy)
  • 15)Patient with embolization or crystal deposition like 1) cholesterol emboli 2) oxalate
  • crystal deposition 3) marantic endocarditis, atrial myxoma, crystal globulins,
  • hypereosinophilic syndrome
  • 16)Patient with high reticulocyte states like sickle cell disease, other severe hemolytic
  • anemias, severe malaria
  • 17)Patient with cutaneous calciphylaxis, Brown recluse spider bite reaction , Intravascular
  • B cell lymphoma

Investigators

Sponsor
GCS Medical College Hospital and Research Centre

Similar Trials

Study of swelling in blood vessels of ski | Clinical Trial